Bergengren O, Pekala KR, Matsoukas K, et al. 2022 update on prostate cancer epidemiology and risk factors—a systematic review. Eur Urol. 2023;84(2):191–206.

Article  PubMed  PubMed Central  Google Scholar 

Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340–51.

Article  PubMed  Google Scholar 

Tsechelidis I, Vrachimis A. PSMA PET in imaging prostate cancer. Front Oncol. 2022;12:831429.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17.

Article  PubMed  Google Scholar 

Roberts MJ, Morton A, Donato P, et al. 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):477–82.

Article  CAS  PubMed  Google Scholar 

Emmett L, Papa N, Counter W, et al. Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database. J Nucl Med. 2024;65(1):94–9.

Article  CAS  PubMed  Google Scholar 

Emmett L, Papa N, Buteau J, et al. The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63(11):1644–50.

CAS  PubMed  PubMed Central  Google Scholar 

Prostate Cancer. Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–690.

Evangelista L, Guglielmo P, Giacoppo G, et al. The evaluation of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for initial staging in intermediate-risk prostate cancer patients: a retrospective multicenter analysis. Diagnostics (Basel). 2024;14(23):2751.

Article  PubMed  Google Scholar 

Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–86.

Article  PubMed  PubMed Central  Google Scholar 

Emmett L, Luining WI, Jager A, et al. The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63:1644–50.

CAS  PubMed  PubMed Central  Google Scholar 

Kovac E, Vertosick EA, Sjoberg DD, et al. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer. BJU Int. 2018;122:1003–9.

Article  PubMed  PubMed Central  Google Scholar 

Claes P, Ahmadi Bidakhvidi N, Giesen A, et al. PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management. Clin Transl Imaging. 2024;12:31–54.

Article  Google Scholar 

Jafari E, Dadgar H, Zarei A, et al. The role of [68Ga]Ga-PSMA PET/CT in primary staging of newly diagnosed prostate cancer: predictive value of PET-derived parameters for risk stratification through machine learning. Clin Transl Imaging. 2024;12:669–82.

Article  Google Scholar 

Seifert R, Eiber M, Herrmann K, et al. The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine? Clin Transl Imaging. 2024;12:1–3.

Article  Google Scholar 

Muralidhar V, Dinh KT, Mahal BA, et al. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015;33:330.e19–330.e25.

Oderda M, Gontero P, Sanchez-Salas R, et al. Gleason score upgrading to 8–10 predicts biochemical recurrence in patients undergoing radical prostatectomy: Analysis on 7310 high-risk patient the EMPaCT database. Eur Urol Suppl. 2015;14:e936.

Article  Google Scholar 

Wang X, Zhang Y, Ji Z, Yang P, et al. Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and meta-analysis. World J Surg Oncol. 2021;19(1):18.

Article  PubMed  PubMed Central  Google Scholar 

Roberts MJ, Morton A, Papa N, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022;49(9):3289–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uslu H, Şahin D, İbişoğlu E, Tatoğlu MT. PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance. Ann Nucl Med. 2024. https://doi.org/10.1007/s12149-024-02004-5.

Article  PubMed  Google Scholar 

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–690.